Home › Funds › Remedium Capital Partners, LLC › DMRA
Remedium Capital Partners, LLC position in DMRA
DAMORA THERAPEUTICS INC · Health Care
Remedium Capital Partners, LLC reported holding 2,045,473 shares of DMRA (DAMORA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$43.5M, representing 15.91% of its reported portfolio and ranking #3 among its reported holdings. Remedium Capital Partners, LLC has disclosed DMRA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Remedium Capital Partners, LLC's DMRA position evolved
Remedium Capital Partners, LLC first disclosed a stake in DMRA in Q4 2025 at 120,473 shares (US$2.8M). The position peaked in Q2 2026 at 2,045,473 shares, worth US$53.2M. Across 4 filings, Remedium Capital Partners, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,045,473 shares valued at US$43.5M. Notable position changes include a 1598% increase in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 120.47K | $2.77M | New |
| Q1 2026 | 2.05M | $52.98M | Add |
| Q2 2026 | 2.05M | $53.20M | Hold |
| Q3 2026 | 2.05M | $43.53M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (DAMORA THERAPEUTICS INC) is a Health Care company. 94 other funds we track also report a position in DMRA — the largest reported positions include Fairmount Funds Management LLC (US$226.6M), Avoro Capital Advisors LLC (US$98.4M), Venrock Adviser, LLC (US$93.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Fairmount Funds Management LLC 8.71M sh · $226.63M · Q2 2026
- Avoro Capital Advisors LLC 3.78M sh · $98.40M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $63.49M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- Bellevue Group AG 1.62M sh · $42.11M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
- Siren, L.L.C. 900.00K sh · $19.15M · Q3 2026
More on Remedium Capital Partners, LLC
FAQ
How long has Remedium Capital Partners, LLC held DMRA?
Remedium Capital Partners, LLC has disclosed DMRA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Remedium Capital Partners, LLC's current position in DMRA?
As of Q3 2026, Remedium Capital Partners, LLC holds 2.05M shares of DMRA (DAMORA THERAPEUTICS INC), valued at $43.53M, representing 15.91% of its reported portfolio and ranking #3.
Has Remedium Capital Partners, LLC been buying or selling DMRA?
In the latest 13F filing (Q3 2026), Remedium Capital Partners, LLC held unchanged its position in DMRA. The position peaked in Q2 2026 at 2.05M shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.